Inogen (INGN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 Jun, 2026Opening remarks and agenda
Meeting opened by the President and CEO, with introductions of directors, officers, auditors, and legal counsel.
Outlined the agenda: formal business followed by a Q&A session.
Confirmed meeting held in accordance with bylaws and Delaware law, with notice and proxy statements mailed to stockholders.
Board and executive committee updates
Vafa Jamali appointed as a new Class I director, effective at the meeting.
Board consists of eight members divided into three classes with staggered terms.
Shareholder proposals
No director nominations were received from stockholders; nominations for directors closed.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inogen
- Diversified platform, new products, and financial turnaround position for sustained growth.INGN
Corporate presentation11 Jun 2026 - Revenue up 3.4% to $85.1M, driven by international growth despite higher net loss.INGN
Q1 202611 May 2026 - Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing28 Apr 2026 - Shareholders will vote on board declassification, equity plan expansion, and key governance changes.INGN
Proxy filing17 Apr 2026 - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Diversifying into respiratory care, achieving financial turnaround, and launching innovative products.INGN
Company presentation20 Mar 2026 - Diversified portfolio and innovation pipeline set to drive growth and profitability.INGN
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - 2025 revenue rose 3.9–4% with improved profitability and a $30M buyback; 2026 targets 6% growth.INGN
Q4 202524 Feb 2026 - Q2 revenue up 6.1% to $88.8M, gross margin 48.1%, net loss narrowed, B2B led growth.INGN
Q2 20242 Feb 2026